Literature DB >> 31758837

Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.

Larissa Otero1,2, Tullia Battaglioli3, Julia Ríos4, Zayda De la Torre5, Nayda Trocones5, Cielo Ordoñez5, Carlos Seas1,2, Patrick Van der Stuyft6.   

Abstract

OBJECTIVE: Contacts of pulmonary tuberculosis (TB) cases are at high risk of TB infection and progression to disease. Close and household contacts and those <5 years old have the highest risk. Isoniazid preventive therapy (IPT) can largely prevent TB disease among infected individuals. International and Peruvian recommendations include TB contact investigation and IPT prescription to eligible contacts. We conducted a study in Lima, Peru, to determine the number of close and household contacts who were evaluated, started on IPT, and who completed it, and the factors associated to compliance with national guidelines.
METHODS: We conducted a longitudinal retrospective study including all TB cases diagnosed between January 2015 and July 2016 in 13 health facilities in south Lima. Treatment cards, TB registers and clinical files were reviewed and data on index cases (sex, age, smear status, TB treatment outcome), contact investigation (sex, age, kinship to the index case, evaluations at month 0, 2 and 6) and health facility (number of TB cases notified per year, proportion of TB cases with treatment success) were extracted. We tabulated frequencies of contact evaluation by contact and index case characteristics. To investigate determinants of IPT initiation and completion, we used generalised linear mixed models.
RESULTS: A total of 2323 contacts were reported by 662 index cases; the median number of contacts per case was four (IQR, 2-5). Evaluation at month 0 was completed by 99.2% (255/257) of contacts <5 and 98.1% (558/569) of contacts aged 5-19 years. Of 191 eligible contacts <5 years old, 70.2% (134) started IPT and 31.4% (42) completed it. Of 395 contacts 5-19 years old, 36.7% (145) started IPT and 32.4% (47) completed it. Factors associated to not starting IPT among contacts <5 years old were being a second-degree relative to the index case (OR 6.6 95CI% 2.6-16.5), not having received a tuberculin skin test (TST) (OR 3.9 95%CI 1.4-10.8), being contact of a smear-negative index case (OR 5.5 95%CI 2.0-15.1) and attending a low-caseload health facility (OR 2.8 95%CI 1.3-6.2). Factors associated to not starting IPT among 5-19 year-olds were age (OR 13.7 95%CI 5.9-32.0 for 16-19 vs. 5-7 years old), being a second-degree relative (OR 3.0 95%CI 1.6-5.6), not having received a TST (OR 5.4, 95%CI 2.5-11.8), being contact of a male index case (OR 2.1 95CI% 1.2-3.5), with smear-negative TB (OR 1.9 95%CI 1.0-3.6), and attending a high-caseload health facility (OR 2.1 95%CI 1.2-3.6). Factors associated to not completing IPT, among contacts who started, were not having received a TST (OR 3.4 95%CI 1.5-7.9 for <5 year-olds, and OR 4.3 95%CI 1.7-10.8 for those 5-19 years old), being contact of an index case with TB treatment outcome other than success (OR 9.3 95%CI 2.6-33.8 for <5 year-olds and OR 15.3 95%CI 1.9-125.8 for those 5-19 years old), and, only for those 5-19 years old, attending a health facility with high caseload (OR 3.2 95%CI 1.4-7.7) and a health facility with low proportion of TB cases with treatment success (OR 4.4 95%CI 1.9-10.2).
CONCLUSIONS: We found partial compliance to TB contact investigation, and identified contact, index case and health facility-related factors associated to IPT start and completion that can guide the TB programme in increasing coverage and quality of this fundamental activity.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  Peru; Pérou; contact investigation; investigation des contacts; isoniazid preventive therapy; paediatric tuberculosis; thérapie préventive à l'isoniazide; tuberculose; tuberculose pédiatrique; tuberculosis

Mesh:

Substances:

Year:  2019        PMID: 31758837      PMCID: PMC7054138          DOI: 10.1111/tmi.13350

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  30 in total

Review 1.  Preventive therapy for latent tuberculosis infection-the promise and the challenges.

Authors:  G J Fox; C C Dobler; B J Marais; J T Denholm
Journal:  Int J Infect Dis       Date:  2016-11-18       Impact factor: 3.623

2.  Adherence to isoniazid preventive therapy in children exposed to tuberculosis: a prospective study from Guinea-Bissau.

Authors:  V F Gomes; C Wejse; I Oliveira; A Andersen; F J Vieira; L J Carlos; C S Vieira; P Aaby; P Gustafson
Journal:  Int J Tuberc Lung Dis       Date:  2011-12       Impact factor: 2.373

3.  Risk of infection and disease with Mycobacterium tuberculosis among children identified through prospective community-based contact screening in Indonesia.

Authors:  Rina Triasih; Colin Robertson; Trevor Duke; Stephen M Graham
Journal:  Trop Med Int Health       Date:  2015-03-06       Impact factor: 2.622

Review 4.  The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.

Authors:  Hannah Alsdurf; Philip C Hill; Alberto Matteelli; Haileyesus Getahun; Dick Menzies
Journal:  Lancet Infect Dis       Date:  2016-08-10       Impact factor: 25.071

Review 5.  Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions.

Authors:  Merrin E Rutherford; Philip C Hill; Rina Triasih; Rebecca Sinfield; Reinout van Crevel; Stephen M Graham
Journal:  Trop Med Int Health       Date:  2012-08-05       Impact factor: 2.622

6.  Contact screening and chemoprophylaxis in India's Revised Tuberculosis Control Programme: a situational analysis.

Authors:  V V Banu Rekha; K Jagarajamma; F Wares; V Chandrasekaran; S Swaminathan
Journal:  Int J Tuberc Lung Dis       Date:  2009-12       Impact factor: 2.373

7.  Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries.

Authors:  Philip C Hill; Merrin E Rutherford; Rick Audas; Reinout van Crevel; Stephen M Graham
Journal:  PLoS Med       Date:  2011-10-11       Impact factor: 11.069

8.  Patient Characteristics Associated with Tuberculosis Treatment Default: A Cohort Study in a High-Incidence Area of Lima, Peru.

Authors:  Brian Lackey; Carlos Seas; Patrick Van der Stuyft; Larissa Otero
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

9.  Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach.

Authors:  Irene Ayakaka; Sara Ackerman; Joseph M Ggita; Phoebe Kajubi; David Dowdy; Jessica E Haberer; Elizabeth Fair; Philip Hopewell; Margaret A Handley; Adithya Cattamanchi; Achilles Katamba; J Lucian Davis
Journal:  Implement Sci       Date:  2017-03-09       Impact factor: 7.327

10.  Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study.

Authors:  Peter J Dodd; Courtney M Yuen; Mercedes C Becerra; Paul Revill; Helen E Jenkins; James A Seddon
Journal:  Lancet Glob Health       Date:  2018-09-25       Impact factor: 26.763

View more
  3 in total

1.  Caregivers' knowledge and perceptions are associated with children's TB preventive treatment completion.

Authors:  J Zeladita-Huaman; C M Yuen; R Zegarra-Chapoñan; M Curisinche-Rojas; V Egusquiza-Pozo
Journal:  Public Health Action       Date:  2021-06-21

2.  Implementation of isoniazid preventive therapy in southern Lima, Peru: an analysis of health center characteristics.

Authors:  Roberto Zegarra-Chapoñan; Lily Victoria Bonadonna; Courtney M Yuen; Martha Brigida Martina-Chávez; Jhon Zeladita-Huaman
Journal:  Infect Dis Poverty       Date:  2021-05-07       Impact factor: 4.520

3.  Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru.

Authors:  Courtney M Yuen; Ana K Millones; Jerome T Galea; Daniela Puma; Judith Jimenez; Leonid Lecca; Mercedes C Becerra; Salmaan Keshavjee
Journal:  BMC Public Health       Date:  2021-01-11       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.